These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6137533)

  • 1. Motor inhibition induced by aporphine derivatives in the mouse.
    Bradbury AJ; Costall B; Naylor RJ; Neumeyer JL
    J Pharm Pharmacol; 1983 Aug; 35(8):494-9. PubMed ID: 6137533
    [No Abstract]   [Full Text] [Related]  

  • 2. On the ability of N-chloroethyl aporphine derivatives to cause irreversible inhibition of dopamine receptor mechanisms.
    Costall B; Fortune DH; Granchelli FE; Law SJ; Naylor RJ; Neumeyer JL; Nohria V
    J Pharm Pharmacol; 1980 Aug; 32(8):571-6. PubMed ID: 6106696
    [No Abstract]   [Full Text] [Related]  

  • 3. Aporphines. 30. (-)-N(2-chloroethyl)-10,11-dihydroxynor-aporphine (chloroethylnorapomorphine), a novel irreversible dopamine receptor antagonist.
    Neumeyer JL; Law SJ; Baldessarini RJ; Kula NS
    J Med Chem; 1980 Jun; 23(6):594-5. PubMed ID: 7392026
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of (-)N-(chloroethyl)-norapomorphine on [3H]-apomorphine binding to striatal dopamine receptors.
    Goosey MW; Doggett NS
    Biochem Pharmacol; 1982 Nov; 31(22):3693-4. PubMed ID: 7181954
    [No Abstract]   [Full Text] [Related]  

  • 5. Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
    Costall B; Naylor RJ
    J Med Chem; 1977 Feb; 20(2):190-6. PubMed ID: 556776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats.
    Pycock CJ; Kerwin RW; Carter CJ
    Nature; 1980 Jul; 286(5768):74-6. PubMed ID: 7393327
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of striatal dopamine release by the selective D-2 dopamine receptor agonist N-0437 is blocked by quinine.
    Cass WA; Zahniser NR
    Synapse; 1990; 5(4):336-7. PubMed ID: 2141733
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice.
    Costall B; Lim SK; Naylor RJ
    Eur J Pharmacol; 1981 Jul; 73(2-3):175-88. PubMed ID: 6118281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation between behavioral effects of (-)-N-(2-chloroethyl)-norapomorphine and D2 dopamine receptor-like activity.
    Helmeste DM
    Eur J Pharmacol; 1983 Nov; 95(3-4):277-81. PubMed ID: 6317413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the enantiomers of SK&F 83566 as specific and stereoselective antagonists at the striatal D-1 dopamine receptor: comparisons with the D-2 enantioselectivity of Ro 22-1319.
    O'Boyle KM; Waddington JL
    Eur J Pharmacol; 1984 Oct; 106(1):219-20. PubMed ID: 6241567
    [No Abstract]   [Full Text] [Related]  

  • 11. Is TL-99 a selective presynaptic dopamine receptor agonist?
    Horn AS; De Vries J; Dijkstra D; Mulder AH
    Eur J Pharmacol; 1982 Sep; 83(1-2):35-45. PubMed ID: 7128699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
    Booth RG; Baldessarini RJ; Kula NS; Gao Y; Zong R; Neumeyer JL
    Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
    Neumeyer JL; Arana GW; Law SJ; Lamont JS; Kula NS; Baldessarini RJ
    J Med Chem; 1981 Dec; 24(12):1440-5. PubMed ID: 7310821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of 7-oxaaporphine derivatives and evaluation of their dopaminergic activity.
    Banzatti C; Carfagna N; Commisso R; Heidempergher F; Pegrassi L; Melloni P
    J Med Chem; 1988 Jul; 31(7):1466-71. PubMed ID: 2968456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of dopamine agonist action to inhibit locomotor activity and to induce stereotyped behaviour in the mouse.
    Bradbury AJ; Cannon JG; Costall B; Naylor RJ
    Eur J Pharmacol; 1984 Oct; 105(1-2):33-47. PubMed ID: 6541588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aporphines as antagonists of dopamine D-1 receptors.
    Schaus JM; Titus RD; Foreman MM; Mason NR; Truex LL
    J Med Chem; 1990 Feb; 33(2):600-7. PubMed ID: 2405158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum.
    Terai M; Hidaka K; Nakamura Y
    Eur J Pharmacol; 1989 Dec; 173(2-3):177-82. PubMed ID: 2576228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic D-amphetamine and phencyclidine: effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems.
    Robertson HA
    Brain Res; 1983 May; 267(1):179-82. PubMed ID: 6860944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.
    Van der Weide J; De Vries JB; Tepper PG; Krause DN; Dubocovich ML; Horn AS
    Eur J Pharmacol; 1988 Mar; 147(2):249-58. PubMed ID: 3130270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.